VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
TAK-280
Preclinical
Small molecule
Takeda
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Metastatic Cancer
Terminated
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Metastatic Cancer
Preclinical
Terminated
Clinical
Trials by Indication
[1]
Metastatic Cancer
1 trial
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Terminated
·
Takeda
·
Preclinical
·
NCT05220098
·
69 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for TAK-280. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
TAK-280 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for TAK-280. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Takeda company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Preclinical
[1]
Company
Takeda
Related News
